{
  "docId": "019de074-71be-772a-8bed-f9d5eaece76b",
  "docSlug": "e4f10758c80bf7a23f09bd201ccd4281",
  "documentTitle": "Alkermes | Investor Presentation Deck | 32 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 32,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "sparse",
  "nDataPoints": 4,
  "notes": "The heatmaps visualize EEG frequency power over time, with red indicating high power (arousal) and blue indicating low power.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-71be-772a-8bed-f9d5eaece76b/20",
  "deckHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b",
  "deckJsonHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b.json",
  "deckAnchorHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.8,
        "x": 0.1,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Cortical Arousal Rat PharmacoEEG heatmaps",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c7fbe41-d10f-4bcc-b960-d09338ce5339",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Selective orexin 2 receptor agonist demonstrated dose-dependent wake duration (shown by red gamma bands and dark blue theta and delta bands)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9660e097-cf21-4835-a81c-30e9710d619b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "PharmacoEEG: Pharmaco-electroencephalography. Alkermes data on file",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dee43d2e-d223-4524-8b03-bdcd64acb280",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Selective Orexin 2 Receptor Agonist Promoted Prolonged Wakefulness in Preclinical In Vivo Studies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76cf38b0-9eda-4ff9-b806-bf94d0154f4a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 8,
      "beatId": "94c87527-871a-454f-af4f-75bda8022c1a",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "LYBALVI prescription growth trends, ALKS 2680 clinical development plan",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "187a0d0b-46a7-4879-95f2-d6fe134e2cb5",
      "evidence": "Orexin Dysfunction: Well Defined Opportunity in Narcolepsy and Other Sleep Disorders",
      "position": 1,
      "objective": "why addressing orexin dysfunction is important",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}